Peter Johnson


Primary position:
Professor of Medical Oncology


The University of Southampton

Peter Johnson graduated from Cambridge University and St Thomas's Medical School. He trained in oncology at St Bartholomew's Hospital, where he was an Imperial Cancer Research Fund Clinical Research Fellow and completed his doctoral research on the Bcl-2 gene, its potential as a therapeutic target in lymphoma and the effects of CD40 ligation on the B-cell surface. He was subsequently a Senior Lecturer in Medical Oncology in the ICRF Cancer Medicine Research Unit, Leeds and took up the Chair of Medical Oncology in Southampton in 1998. He leads the Southampton Cancer Research UK Centre, responsible for bringing together a broad multidisciplinary group of basic, translational and clinical researchers, and linking the laboratory research to the extensive clinical practice in cancer treatment in the Southampton Cancer Centre. Southampton hosts an Experimental Cancer Medicine Centre and a Clinical Trials Unit, both with core support from NIHR and CR UK. He was appointed Chief Clinician for Cancer Research UK in 2008.


BA, University of Cambridge 1982
MB BChir, University of Cambridge 1985
MA,University of Cambridge 1986
MRCP, Royal College of Physicians 1988
MD, University of Cambridge 1994
FRCP, Royal College of Physicians 1998

Appointments held

House Physician, St Thomas’s Hospital, London. 1986

SHO rotations in General Medicine, Guy’s & St Bartholomew’s Hospitals, London. 1986-1988

Registrar in General Medicine, Frimley Park Hospital, Surrey. 1988-1989

Registrar in Medical Oncology & ICRF Clinical Research Fellow, St Bartholomew’s, London. 1989-1994

Senior Lecturer in Medical Oncology, University of Leeds. 1994-1988

Prof of Medical Oncology, Faculty of Medicine, University of Southampton 1998 to current

Honorary Consultant in Medical Oncology, Southampton University Hospitals NHS Trust 1998 to current

Professor Peter Johnson's photo


The University of Southampton's electronic library (e-prints)


Blunt, Matthew D., Carter, Matthew J., Larrayoz, Marta, Smith, Lindsay D., Aguilar-Hernandez, Maria, Cox, Kerry L., Tipton, Thomas R.W., Reynolds, Mark, Murphy, Sarah, Lemm, Elizabeth, Dias, Samantha, Duncombe, Andrew S., Strefford, Jonathan C., Johnson, Peter W.M., Forconi, Francesco, Stevenson, Freda K., Packham, Graham, Cragg, Mark S. and Steele, Andrew J. (2015) The PI3K/mTOR inhibitor PF-04691502 induces apoptosis and inhibits microenvironmental signaling in CLL and the Eμ-TCL1 mouse model. Blood, 1-25. (doi:10.1182/blood-2014-11-610329). (PMID:25957390).
Roghanian, Ali, Teige, Ingrid, Mårtensson, Linda, Cox, Kerry L., Kovacek, Mathilda, Ljungars, Anne, Mattson, Jenny, Sundberg, Annika, Vaughan, Andrew T., Shah, Vallari, Smyth, Neil R., Sheth, Bhavwanti, Chan, H.T. Claude, Li, Zhan-Chun, Williams, Emily L., Manfredi, Giusi, Oldham, Robert J., Mockridge, C. Ian, James, Sonya A., Dahal, Lekh N., Hussain, Khiyam, Nilsson, Björn, Verbeek, J. Sjef, Juliusson, Gunnar, Hansson, Markus, Jerkeman, Mats, Johnson, Peter W.M., Davies, Andrew, Beers, Stephen A., Glennie, Martin J., Frendéus, Björn and Cragg, Mark S. (2015) Antagonistic Human FcγRIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo. Cancer Cell, 27, (4), 473-488. (doi:10.1016/j.ccell.2015.03.005). (PMID:25873171).
White, Ann L., Chan, H.T. Claude, French, Ruth R., Willoughby, Jane E., Mockridge, C. Ian, Roghanian, Ali, Penfold, Christine A., Booth, Steven G., Dodhy, Ali, Polak, Marta E., Potter, Elizabeth A., Ardern-Jones, Michael R., Verbeek, J. Sjef, Johnson, Peter W.M., Al-Shamkhani, Aymen, Cragg, Mark S., Beers, Stephen A. and Glennie, Martin J. (2015) Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies. Cancer Cell, 27, (1), 138-148. (doi:10.1016/j.ccell.2014.11.001). (PMID:25500122).
Chowdhury, Ferdousi, Johnson, Peter, Glennie, Martin and Williams, Anthony (2014) Ex vivo assays of dendritic cell activation and cytokine profiles as predictors of in vivo effects in an anti-human CD40 monoclonal antibody ChiLob 7/4 phase I trial. Cancer Immunology Research, 2, (3), 229-240. (doi:10.1158/2326-6066.CIR-13-0070). (PMID:24778319).
Taraban, V.Y., Rowley, T.F., Kerr , J.P., Willoughby, Jane E., Johnson, Peter W.M., Al-Shamkhani, A. and Buchan, S.L. (2013) CD27 costimulation contributes substantially to the expansion of functional memory CD8+ T cells after peptide immunization. European Journal of Immunology, n/a, 1-29. (doi:10.1002/eji.201343579). (PMID:24002868).
Coelho, Vânia, Krysov, Sergey, Steele, Andrew, Sanchez-Hidalgo, Marina, Johnson, Peter W., Chana, Prabhjoat S., Packham, Graham, Stevenson, Freda K. and Forconi, Francesco (2013) Identification in CLL of circulating intraclonal subgroups with varying B-cell receptor expression and function. Blood, 122, (15), 2664-2672. (doi:10.1182/blood-2013-02-485425). (PMID:23954894).
Williams, Emily L., Dunn, Stuart N., James, Sonya, Johnson, Peter W., Cragg, Mark S., Glennie, Martin J. and Gray, Juliet C. (2013) Immunomodulatory monoclonal antibodies combined with peptide vaccination provide potent immunotherapy in an aggressive murine neuroblastoma model. Clinical Cancer Research, 19, (13), 3545-3555. (doi:10.1158/1078-0432.CCR-12-3226). (PMID:23649004).
King, Ben C., Hamblin, Angela D., Savage, Philip M., Douglas, Leon R., Hansen, Ted H., French, Ruth R., Johnson, Peter W.M. and Glennie, Martin J. (2013) Antibody-peptide-MHC fusion conjugates target non-cognate T cells to kill tumour cells. Cancer Immunology Immunotherapy, 62, (6), 1093-1105. (doi:10.1007/s00262-013-1408-8). (PMID:23604105).
Lee, Chern Siang, Cragg, Mark, Glennie, Martin and Johnson, Peter (2013) Novel antibodies targeting immune regulatory checkpoints for cancer therapy. British Journal of Clinical Pharmacology (doi:10.1111/bcp.12164). (PMID:23701301).
Publicover, Amy, Richardson, Deborah S., Davies, Andrew, Hill, Kate S., Hurlock, Carol, Hutchins, David, Jenner, Matthew W., Johnson, Peter, Lamb, Jane, Launders, Harriet, McKeag, Nikki, Newman, Joan and Orchard, Kim H. (2013) Use of a biosimilar granulocyte colony-stimulating factor for peripheral blood stem cell mobilization: an analysis of mobilization and engraftment. British Journal of Haematology (doi:10.1111/bjh.12345). (PMID:23614650).
White, Ann L., Chan, H. T. Claude, French, Ruth R., Beers, Stephen A., Cragg, Mark S., Johnson, Peter W. M. and Glennie, Martin J. (2013) FcγRΙΙB controls the potency of agonistic anti-TNFR mAbs. Cancer Immunology and Immunotherapy (doi:10.1007/s00262-013-1398-6). (PMID:23543215).
Fayad, Luis, Offner, Fritz, Smith, Mitchell R., Verhoef, Gregor, Johnson, Peter, Kaufman, Jonathan L., Rohatiner, Ama, Advani, Anjali, Foran, James, Hess, Georg, Coiffier, Bertrand, Czuczman, Myron, Giné, Eva, Durrant, Simon, Kneissl, Michelle, Luu, Kenneth T., Hua, Steven Y., Boni, Joseph, Vandendries, Erik and Dang, Nam H. (2013) Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with Rituximab. Journal of Clinical Oncology (doi:10.1200/JCO.2012.42.7211). (PMID:23295790).
Zucca, Emanuele, Conconi, Annarita, Laszlo, Daniele, López-Guillermo, Armando, Bouabdallah, Reda, Coiffier, Bertrand, Sebban, Catherine, Jardin, Fabrice, Vitolo, Umberto, Morschhauser, Franck, Pileri, Stefano A, Copie-Bergman, Christiane, Campo, Elias, Jack, Andrew, Floriani, Irene, Johnson, Peter, Martelli, Maurizio, Cavalli, Franco, Martinelli, Giovanni and Thieblemont, Catherine (2013) Addition of Rituximab to Chlorambucil Produces Superior Event-Free Survival in the Treatment of Patients With Extranodal Marginal-Zone B-Cell Lymphoma: 5-Year Analysis of the IELSG-19 Randomized Study. Journal of Clinical Oncology (doi:10.1200/JCO.2011.40.6272). (PMID:23295789).
Cunningham, D., Hawkes, E.A., Jack, A., Qian, W., Smith, P., Mouncey, P., Pocock, C., Ardeshna, K.M., Radford, J.A., McMillan, A., Davies, J., Turner, D., Kruger, A., Johnson, P., Gambell, J. and Linch, D. (2013) Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. The Lancet, 381, (9880), 1817-1826. (doi:10.1016/S0140-6736(13)60313-X).
Nicolosi Guidicelli, Sabrina, Lopez-Guillermo, Armando, Falcone, Umberto, Conconi, Annarita, Christinat, Alexandre, Rodriguez-Abreu, Delvys, Grisanti, Salvatore, Lobetti-Bodoni, Chiara, Piffaretti, Jean Claude, Johnson, Peter W, Mombelli, Giorgio, Cerny, Andreas, Montserrat, Emili, Cavalli, Franco and Zucca, Emanuele (2012) Hepatitis C virus and GBV-C virus prevalence among patients with B-cell lymphoma in different European regions: a case-control study of the International Extranodal Lymphoma Study Group. Hematological Oncology, 30, (3), 137-142. (doi:10.1002/hon.1015). (PMID:22105737).
Crabb, Simon J., Bradbury, Jennifer, Nolan, Luke, Selman, Diana, Muthuramalingam, Sethupathi R., Cave, Judith, Johnson, Peter W.M. and Ottensmeier, Christian (2012) A phase I clinical trial of irinotecan and carboplatin in patients with extensive stage small cell lung cancer. Chemotherapy, 58, (4), 257-263. (doi:10.1159/000341274). (PMID:22907396).
Crabb, Simon J., Bradbury, J., Nolan, L., Selman, D., Muthuramalingam, Sethupathi R., Cave, Judith, Johnson, Peter W.M. and Ottensmeier, Christian (2012) A phase I clinical trial of Irinotecan and Carboplatin in patients with extensive stage small cell lung cancer. Chemotherapy, 58, (4), 257-263. (doi:10.1159/000341274). (PMID:22907396).
Dean, H. F, Cazaly, A, Hurlock, C., Borras, J., Williams, A. P., Johnson, Peter W.M. and Davies, A. J. (2012) Defects in lymphocyte subsets and serological memory persist a median of 10 years after high-dose therapy and autologous progenitor cell rescue for malignant lymphoma. Bone Marrow Transplantation (doi:10.1038/bmt.2012.73). (PMID:22580768).
Shaw, Emily C. and Johnson, Peter W. M. (2012) Stratified medicine for cancer therapy. Drug Discovery Today, 17, (5-6), 261-268. (doi:10.1016/j.drudis.2012.02.004). (PMID:22493785).
Lim, Sean H. and Johnson, Peter W.M. (2011) Chemotherapy: advanced Hodgkin lymphoma - balancing toxicity and cure. Nature Reviews Clinical Oncology, 8, (11), 634-636. (doi:10.1038/nrclinonc.2011.137). (PMID:21894205).
Lim, Sean, Vaughan, Andrew, Ashton-Key, Margaret, Williams, E.L., Dixon, S., Chan, H.T. Claude, Beers, Stephen, French, R.R., Cox, K., Davies, AJ, Potter, Kathleen N., Mockridge, C.I., Oscier, David G., Johnson, P.W.M., Cragg, Mark and Glennie, Martin (2011) Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy. Blood, 118, (9), 2530-2540. (doi:10.1182/blood-2011-01-330357). (PMID:21768293).
Hayden, Annette, Johnson, Peter W.M., Packham, Graham and Crabb, Simon J. (2011) S-adenosylhomocysteine hydrolase inhibition by 3-deazaneplanocin A analogues induces anti-cancer effects in breast cancer cell lines and synergy with both histone deacetylase and HER2 inhibition. Breast Cancer Research and Treatment, 127, (1), 109-119. (doi:10.1007/s10549-010-0982-0). (PMID:20556507).
Raponi, Michela, Kralovicova, Jana, Copson, Ellen, Divina, Petr, Eccles, Diana, Johnson, Peter, Baralle, Diana and Vorechovsky, Igor (2011) Prediction of single-nucleotide substitutions that result in exon skipping: identification of a splicing silencer in BRCA1 exon 6. Human Mutation, 32, (4), 436-444. (doi:10.1002/humu.21458). (PMID:21309043).
Barrington, S.F., Mackewn, J.E., Schleyer, P., Marsden, P.K., Mikhaeel, N.G., Qian, W., Mouncey, P., Patrick, P., Popova, B., Johnson, Peter W.M., Radford, J. and O'Doherty, M.J. (2011) Establishment of a UK-wide network to facilitate the acquisition of quality assured FDG-PET data for clinical trials in lymphoma. Annals of Oncology, 22, (3), 739-745. (doi:10.1093/annonc/mdq428). (PMID:20813876).
Danson, S.J., Johnson, Peter W.M., Ward, T.H., Dawson, M., Denneny, O., Dickinson, G., Aarons, L., Watson, A., Jowle, D., Cummings, J., Robson, L., Halbert, G., Dive, C. and Ranson, M. (2011) Phase I pharmacokinetic and pharmacodynamic study of the bioreductive drug RH1. Annals of Oncology (doi:10.1093/annonc/mdq638). (PMID:21378203).
Chowdhury, F., Tutt, A.L., Chan, C., Glennie, M. and Johnson, P.W. (2010) Development, validation and application of ELISAs for pharmacokinetic and HACA assessment of a chimeric anti-CD40 monoclonal antibody in human serum. Journal of Immunological Methods, 363, (1), Winter Issue, 1-8. (doi:10.1016/j.jim.2010.09.023). (PMID:20869964).
Agathocleous, Agathoclis, Rohatiner, Ama, Rule, Simon, Hunter, Hannah, Kerr, Jonathan Paul, Neeson, Susan M., Mathews, Janet, Strauss, Sandra, Montoto, Silvia, Johnson, Peter, Radford, John and Lister, Andrew (2010) Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenstro¨m macroglobulinaemia. British Journal of Haematology, 151, (4), 346-353. (doi:10.1111/(ISSN)1365-2141). (PMID:20880120).
Coelho, Vania, Krysov, Sergey, Ghaemmaghami, Amir M., Emara, Mohamed, Potter, Kathleen N., Johnson, Peter, Packham, Graham, Martinez-Pomares, Luisa and Stevenson, Freda K. (2010) Glycosylation of surface Ig creates a functional bridge between human follicular lymphoma and microenvironmental lectins. Proceedings of the National Academy of Sciences of the United States of America, 107, (43), 18587-18592. (doi:10.1073/pnas.1009388107). (PMID:20937880).
Stevenson, Freda K and Johnson, Peter W. M. (2010) Harnessing innate immunity to suppress lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 28, (28), 4295-4296. (doi:10.1200/JCO.2010.30.4212). (PMID:20697067).
Wheater, Matthew J., Johnson, Peter W.M. and Blaydes, Jeremy P. (2010) The role of MNK proteins and eIF4E phosphorylation in breast cancer cell proliferation and survival. Cancer Biology & Therapy, 10, (7), 728-735. (doi:10.4161/cbt.10.7.12965). (PMID:20686366).
Johnson, P.W.M., Sydes, M.R., Hancock, B.W., Cullen, M., Radford, J.A. and Stenning, S.P. (2010) Consolidation radiotherapy in patients with advanced Hodgkin lymphoma: survival data from the UKLG LY09 randomised controlled trial (ISRCTN97144519). Journal of Clinical Oncology, 28, (20), 3352-3359. (doi:10.1200/JCO.2009.26.0323). (PMID:20498402).
Beers, Stephen A., French, Ruth R., Chan, Claude H.T., Lim, Sean H., Jarrett, Timothy C., Mora Vidal, Regina, Wijayaweera, Sahan S., Dixon, Sandra V., Kim, Hyung J. , Cox, Kerry L. , Kerr, Jonathan P. , Johnston, David A. , Johnson, Peter W.M. , Verbeek, Sjef , Glennie, Martin J. and Cragg, Mark S. (2010) Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood, 115, (25), 5191-5201. (doi:10.1182/blood-2010-01-263533). (PMID:20223920).
Chowdhury, Ferdousi, Johnson, Peter and Williams, Antony Peter (2010) Enumeration and phenotypic assessment of human plasmacytoid and myeloid dendritic cells in whole blood. Cytometry Part A (doi:10.1002/cyto.a.20872).
Lim, Sean H., Beers, Stephen A., French, Ruth R., Johnson, Peter W., Glennie, Martin J. and Cragg, Mark S. (2010) Anti-CD20 monoclonal antibodies: historical and future perspectives. Haematologica, 95, (1), 135-143. (doi:10.3324/haematol.2008.001628). (PMID:19773256).
Barrington, S.F., Quian, W., Somer, E.J., Franceschetto, A., Bagni, B., Brun, E., Almquist, H., Loft, A., Hojgaard, L., Federico, M., Gallamini, A., Smith, P., Johnson, Peter W.M., Radford, J. and O'Doherty, M.J. (2010) Concordance between four European Centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. European Journal of Nuclear Medicine and Molecular Imaging (In Press).
Hoskin, Peter J., Lowry, Lisa, Horwich, Alan, Jack, Andrew, Mead, Ben, Hancock, Barry W., Smith, Paul, Qian, Wendi, Patrick, Philippa, Popova, Bilyana, Pettitt, Andrew, Cunningham, David, Pettengell, Ruth, Sweetenham, John, Linch, David and Johnson, Peter W.M. (2009) Randomised comparison of the Stanford V regimen and ABVD in the treatment of advanced Hodgkin's lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. Journal of Clinical Oncology, 27, (32), 5390-5396. (doi:10.1200/JCO.2009.23.3239).
Sharp, Adam, Cutress, Ramsey I., Johnson, Peter W.M., Packham, Graham and Townsend, Paul A. (2009) Short peptides derived from the BAG-1 C-terminus inhibit the interaction between BAG-1 and HSC70 and decrease breast cancer cell growth. FEBS Letters, 583, (21), 3405-3411. (doi:10.1016/j.febslet.2009.09.047).
Sharp, Adam, Crabb, Simon J., Johnson, Peter W.M., Hague, Angela, Cutress, Ramsey, Townsend, Paul A., Ganesan, A. and Packham, Graham (2009) Thioflavin S (NSC71948) interferes with Bcl-2-associated athanogene (BAG-1)-mediated protein-protein interactions. Journal of Pharmacology and Experimental Therapeutics, 331, (2), 680-689. (doi:10.1124/jpet.109.153601).
Valle, J.W., Wasan, H., Johnson, P., Jones, E., Dixon, L., Swindell, R., Baka, S., Maraveyas, A., Corrie, P., Falk, S., Golins, S., Lofts, F., Evans, L., Meyer, T., Anthoney, A., Iveson, T., Highley, M., Osborne, R. and Bridgewater, J. (2009) Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - the UK ABC-01 study. British Journal of Cancer, 101, (4), 621-627. (doi:10.1038/sj.bjc.6605211).
Owadally, Waheeda, Sydes, Matthew, Radford, John, Hancock, Barry, Cullen, Michael, Stenning, Sally and Johnson, Peter (2009) Initial dose intensity has limited impact on the outcome of ABVD chemotherapy for advanced Hodgkin Lymphoma (HL): data from UKLG LY09 (ISRCTN97144519). Annals of Oncology (In Press).
Chowdhury, Ferdousi, Williams, Anthiny and Johnson, Peter (2009) Validation and comparison of two multiplex technologies, Luminex® and Mesoscale Discovery, for human cytokine profiling. Journal of Immunological Methods, 340, (1), 55-64. (doi:10.1016/j.jim.2008.10.002).
Illidge, Tim M., Bayne, Mike, Brown, Nicholas S., Chilton, Samantha, Cragg, Mark S., Glennie, Martin J., Du, Yong, Lewington, Valerie, Smart, James, Thom, James, Zivanovic, Maureen and Johnson, Peter W.M. (2008) Phase 1/2 study of fractionated 131I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy. Blood, 113, (7), 1412-1421. (doi:10.1182/blood-2008-08-175653). (PMID:19074729).
Nolan, L., Johnson, P.W.M., Ganesan, A., Packham, G. and Crabb, S.J. (2008) Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential? British Journal of Cancer, 99, 689-694. (doi:10.1038/sj.bjc.6604557).
Gray, Juliet C., French, Ruth R., James, Sonya, Al-Shamkhani, Aymen, Johnson, Peter W. and Glennie, Martin J. (2008) Optimising anti-tumour CD8 T-cell responses using combinations of immunomodulatory antibodies. European Journal of Immunology, 38, (9), 2499-2511. (doi:10.1002/eji.200838208). (PMID:18792403).
Crabb, S.J., Howell, M., Rogers, H., Ishfaq, M., Yurek-George, A., Carey, K., Pickering, B.M., East, P., Mitter, R., Maeda, S., Johnson, P.W.M., Townsend, P., Shin-Ya, K., Yoshida, M., Ganesan, A. and Packham, G. (2008) Characterisation of the in vitro activity of the depsipeptide histone deacetylase inhibitor spiruchostatin. Biochemical Pharmacology, 76, (4), 463-475. (doi:10.1016/j.bcp.2008.06.004). (PMID:18611394).
Newell, L., Pearson, I., Nyak, N., Luna, L., Hall, R. and Johnson, P. (2008) Multifocal ALK+ primary cutaneous anaplastic large cell lymphoma in an adolescent. British Journal of Dermatology, 159, (s1), 94-94. (doi:10.1111/j.1365-2133.2008.08571.x).
Walshe, Claire A., Beers, S.A., French, Ruth R., Chan, H.T. Claude, Johnson, P. W., Packham, Graham, Glennie, Martin J. and Cragg, Mark S. (2008) Induction of cytosolic calcium flux by CD20 Is dependent upon B cell antigen receptor signaling. Journal of Biological Chemistry, 283, (25), 16971-16984. (doi:10.1074/jbc.M708459200).
Crabb, Simon J., Hague, Angela, Johnson, Peter W.M. and Packham, Graham (2008) BAG-1 inhibits PPARgamma-induced cell death, but not PPARgamma-induced transcription, cell cycle arrest or differentiation in breast cancer cells. Oncology Reports, 19, (3), 689-696.
Parker, K.A., Walker, R., Akinwunmi, J., Glaysher, S., Knight, L.A., Johnson, P., Etherington, A., Gabriel, F.G., Higgins, S., Pilkington, G.J. and Cree, I.A. (2008) Genetic and metabolic predictors of chemosensitivity in primary brain tumours. Neuropathology and Applied Neurobiology, 34, (Supplement 1), 21-22. (doi:10.1111/j.1365-2990.2007.00922.x).
Johnson, P. W., Sydes, M. R., Hancock, B., Cullen, M., Stenning, S. and Radford, J. (2008) Myeloablative therapy for recurrent Hodgkin lymphoma: Good success rates irrespective of previous treatments in the UKLG LY09 trial (ISRCTN97144519)4. Annals of Oncology, 19, 91-91.
Johnson, Peter W. and Davies, Andrew J. (2008) Primary mediastinal B-cell lymphoma. Hematology, 2008, (1), 349-358. (doi:10.1182/asheducation-2008.1.349). (PMID:19074109).
Davies, A. J., Radford, J. A., Rohatiner, A. Z., Linton, K. M., Matthews, J., Johnson, P. W. and Lister, T. A. (2008) Long-term follow-up of patients treated with tositumomab and I-131 tositumomab (BEXXAR (TM))5. Annals of Oncology, 19, 181-181.
Hagenbeek, A., Gadeberg, O., Johnson, P., Pedersen, L.M., Walewski, J., Hellmann, A., Link, B.K., Robak, T., Wojtukiewicz, M., Pfreundschuh, M., Kneba, M., Engert, A., Sonneveld, P., Flensburg, M., Petersen, J., Losic, N. and Radford, J. (2008) First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood, 111, (12), 5486-5495. (doi:10.1182/blood-2007-10-117671).
Johnson, P.W.M. (2008) New targets for lymphoma treatment. Annals of Oncology, 19, (4), 56-59.
Kerr, J.P., Turner, M., Shton-Key, M., Mead, G.M. and Johnson, P.W.M. (2008) Intestinal strictures: a new complication of treatment for primary gastrointestinal diffuse large B-cell lymphoma. British Journal of Haematology, 140, (6), 712-714. (doi:10.1111/j.1365-2141.2007.06950.x).
Agathocleous, A., Rule, S., Johnson, P., Radford, J.A., Lafon, N., Hunter, H., Kerr, J.P., Neeson, S.M., Matthews, J., Strauss, S., Montoto, S., Rohatiner, A.Z.S. and Lister, T.A. (2007) Preliminary results of a phase I/II study of weekly or twice weekly bortezomib in combination with rituximab, in patients with follicular lymphoma, mantle cell lymphoma and Waldenström's macroglobulinaemia. Blood, 110, (11), p.754A.
Johnson, P., Federico, M., Enblad, G., Burton, C., Smith, P., Qian, W., O'Doherty, M. and Radford, J. (2007) Response-adapted therapy using FDG-PET scanning after initial ABVD: the UK NCRI, Italian and Nordic trial in advanced Hodgkin lymphoma. Haematologica, 92, (Supplement 5), 7-8.
Radford, J.A., Barrington, S.F., O'Doherty, M.J., Qian, W., Mouncey, P., Pettengell, R., Hoskin, P., Bessell, E.M., Coltart, R.S., Cunningham, D., Culligan, D., Hatton, C., Johnson, P.W.M., Kruger, A., Linch, D., Lister, T.A., Marcus, R., Sadullah, S., Wimperis, J., Hancock, B.W. and Illidge, T. (2007) Interim results of a UK NCRI randomised trial comparing involved field radiotherapy with no further treatment after 3 cycles ABVD and a negative PET scan in clinical stages IA/IIA Hodgkin lymphoma. Haematologica, 92, (Supplement 5), p.32.
Taylor, Mark, Bolton, Louise M., Johnson, Peter, Elliott, Tim and Murray, Nick (2007) Breast cancer is a promising target for vaccination using cancer-testis antigens known to elicit immune responses. Breast Cancer Research, 9, (4, R46), 7pp. (doi:10.1186/bcr1749).
Boleti, E and Johnson, PWM (2007) Primary mediastinal B-cell lymphoma. Hematological Oncology, 25, (4), 157-163. (doi:10.1002/hon.818).
Johnson, P.W.M., Sydes, M.R., Stenning, S.P., Cullen, M.H., Radford, J.A. and Hancock, B.W., Engert, Andreas (ed.) (2007) Initial dose intensity has limited impact on the outcome of ABVD chemotherapy for advanced Hodgkin's Lymphoma (HL): Data from UKLG LY09 (ISRCTN97144519). Haematologica, 92, (Suppl/5-P111), 68-69.
Du, Yong, Honeychurch, Jamie, Glennie, Martin, Johnson, Peter and Illidge, Tim (2007) Microscopic intratumoral dosimetry of radiolabeled antibodies is a critical determinant of successful radioimmunotherapy in B-cell lymphoma. Cancer Research, 67, (3), 1335-1343. (doi:10.1158/0008-5472.CAN-06-2495).
Nolan, L., Lorigan, P., Chilton, S., Newman, J., Else, R., Smith, P., Linch, D., Sweetenham, J.W. and Johnson, P.W. (2007) Low-dose lenograstim is as effective as standard dose in shortening neutrophil engraftment time following myeloablative chemotherapy and peripheral blood progenitor cell rescue. British Journal of Haematology, 137, (5), 436-442. (doi:10.1111/j.1365-2141.2007.06587.x).
French, Ruth R., Taraban, Vadim Y., Crowther, Graham R., Rowley, Tania F., Gray, Juliet C., Johnson, Peter W., Tutt, Alison L., Al-Shamkhani, Aymen and Glennie, Martin J. (2007) Eradication of lymphoma by CD8 T cells following anti-CD40 monoclonal antibody therapy is critically dependent on CD27 costimulation. Blood, 109, (11), 4810-4815. (doi:10.1182/blood-2006-11-057216).
Habens, F., Lapham, A.S., Dallman, C.L., Pickering, B.M., Michels, J., Marcusson, E.G., Johnson, P.W.M. and Packham, G. (2007) Distinct promoters mediate constitutive and inducible Bcl-X-L expression in malignant lymphocytes. Oncogene, 26, (13), 1910-1919. (doi:10.1038/sj.onc.1209979).
Pickering, B.M., De Mel, S., Lee, M., Howell, M., Habens, F., Dallman, C.L., Neville, L.A., Potter, K.N., Mann, J., Mann, D.A., Johnson, P.W.M., Stevenson, F.K. and Packham, G. (2007) Pharmacological inhibitors of NF-kappa B accelerate apoptosis in chronic lymphocytic leukaemia cells. Oncogene, 26, (8), 1166-1177. (doi:10.1038/sj.onc.1209897).
Wright, J., Johnson, P., Smith, P., Horsman, J.M. and Hancock, B.W. (2007) T cell non-Hodgkin's lymphoma: Treatment outcomes and survival in 3 large UK centres. Acta Haematologica, 118, (2), 123-125. (doi:10.1159/000107742).
d'Amore, Francesco, Relander, Thomas, Jerkeman, Mats, Hagberg, Hans, Osterborg, Anders, Johnson, Peter, Radford, John A., Hancock, Barry W., Gramatzki, Martin, Schmitz, Norbert, Tilly, Herve, Morschhauser, Franck, Lisby, STeen and Baadsgaard, Ole (2006) Zanolimumab, a fully human monoclonal antibody: preliminary results of an ongoing clinical trial in CD4+ peripheral T-cell lymphomas (PTCL). Blood, 108, (11), p.770A.
Johnson, Peter W.M., Radford, John A., Cullen, Michael H., Sydes, Matthew R., Stenning, Sally P. and Hancock, Barry W. (2006) Comparison of outcomes in studies of advanced Hodgkin's lymphoma. Journal of Clinical Oncology, 24, (20), pp.3309. (doi:10.1200/JCO.2006.06.2976).
Nolan, L., Chilton, S., Lorigan, P., Else, R., Smith, P., Sweetenham, J. W. and Johnson, P. W. (2006) Randomised, placebo-controlled, trial comparing low dose versus standard dose Lenograstim (L) following myeloablative chemotherapy (HDT) and peripheral blood progenitor cell rescue [PBPCR) for lymphoma. Journal of Clinical Oncology, 24, (18S), 452S-452S.
Bhandari, Pradeep, Bateman, Adrian C., Mehta, Raj L., Stacey, Bernard S.F., Johnson, Penny, Cree, Ian A., Di Nicolantonio, Federica and Patel, Praful (2006) Prognostic significance of cyclooxygenase-2 (COX-2) expression in patients with surgically resectable adenocarcinoma of the oesophagus. BMC Cancer, 6, (Article no. 134), 9pp.. (doi:10.1186/1471-2407-6-134).
Copson, Ellen R., White, Helen E., Blaydes, Jeremy P., Robinson, David O., Johnson, Peter W. and Eccles, Diana M. (2006) Influence of the MDM2 single nucleotide polymorphism SNP309 on tumour development in BRCA1 mutation carriers. BMC Cancer, 6, (80) (doi:10.1186/1471-2407-6-80).
Orchard, K.H., Cooper, M., Lewington, V., Tristam, M., Zivanovic, M., Thom, J., Quadri, S., Richardson, D., Causer, L. and Johnson, P. (2006) Targeted radiotherapy in haematopoietic stem cell transplantation: results of a phase I trial using an Yttrium-90-labelled anti-CD66 murine monoclonal antibody demonstrating consistent BM targeting. Bone Marrow Transplantation, 37, (Supplement 1), S45-S46. (doi:10.1038/sj.bmt.1705323).
Hill, K.S., Hurlock, C.A., Richardson, D., Johnson, P., Jonas, M., McKeag, N., Newman, J., Kitchker, V., Churchill, S. and Orchard, K. (2006) Indications for and outcome of transfer to the intensive care unit for haemopoietic stem cell transplant patients. Bone Marrow Transplantation, 37, (Supplement 1), pp.S181. (doi:10.1038/sj.bmt.1705324).
Gray, J.C., Johnson, P.W.M. and Glennie, M.J. (2006) Therapeutic potential of immunostimulatory monoclonal antibodies. Clinical Science, 111, (2), 93-106.
Strauss, S.J., Maharaj, L., Hoare, S., Johnson, P.W., Radford, J.A., Vinnecombe, S., Millard, L., Rohatiner, A., Boral, A., Trehu, E., Schenkein, D., Balkwill, F., Joel, S.P. and Lister, T.A. (2006) Bortezomib therapy in patients with relapsed or refractory lymphoma: Potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. Journal of Clinical Oncology, 24, (13), 2105-2112. (doi:10.1200/JCO.2005.04.6789).
Orchard, K.H., Cooper, M., Lewington, V., Tristam, M., Zivanovic, M., Thom, J., Quadri, S., Richardson, D., Causer, L. and Johnson, P. (2006) Targeted radiotherapy in the conditioning prior to haematopoietic stem cell transplantation: Results of a phase I trial using an yttrium-90-labelled anti-CD66 murine monoclonal antibody demonstrating consistently high BM uptake. Biology of Blood and Marrow Transplantation, 12, (2), 10-11. (doi:10.1016/j.bbmt.2005.11.036).
Guidicelli-Nicolosi, S., Rodriguez-Abreu, D., Conconi, A., Grisanti, S., Lopez-Guillermo, A., Johnson, P.W., Montserrat, E., Cavalli, F., Piffaretti, J.C. and Zucca, E. (2006) Prevalence of hepatitis C virus and GB-C virus infection among patients with B-cell non-Hodgkin's lymphoma: A case-control study of the International Extranodal Lymphoma Study Group. Annals of Oncology, 17, p.203.
Sanderson, R.N., Johnson, P.R., Moorman, A.V., Roman, E., Willett, E., Taylor, P.R., Proctor, S.J., Bown, N., Ogston, S. and Bowen, D.T. (2006) Population-based demographic study of karyotypes in 1709 patients with adult Acute Myeloid Leukemia. Leukemia, 20, (3), 444-450. (doi:10.1038/sj.leu.2404055).
Danson, S., Johnson, P., Ward, T., Dawson, M., Denneny, O., Cummings, J., Jowle, D., Howard, E., Dive, C. and Ranson, M. (2005) Phase I pharmacokinetic (PK) and pharmacodynamic (PD) trial of the bioreductive drug RH140. Clinical Cancer Research, 11, (24), p.9150S.
Michels, J., Foria, V., Packham, G., Mead, B. and Johnson, P. (2005) Expression of the anti-apoptotic MCL-1 is a marker of grade and prognosis in follicular lymphoma (FL). Annals of Oncology, 16, supplement 5, v106-v107. (doi:10.1093/annonc/mdi567).
Johnson, P.W.M., Radford, J.A., Cullen, M.H., Sydes, M.R., Walewski, J., Jack, A.S., MacLennan, K.A., Stenning, S.P., Clawson, S., Smith, P., Ryder, D. and Hancock, B.W. (2005) Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). Journal of Clinical Oncology, 23, (36), 9208-9218. (doi:10.1200/JCO.2005.03.2151).
Johnson, Peter, Geldart, Thomas, Fumoleau, Pierre, Pinel, Marie-Claire, Nguyen, Laurent and Judson, Ian (2005) Phase I study of Vinflunine administered as a 10-minute infusion on days 1 and 8 every 3 weeks. Investigational new drugs, 24, (3), 223-231. (doi:10.1007/s10637-005-3902-0).
Rudd, R.M., Gower, N.H., Spiro, S.G., Eisen, T.G., Harper, P.G., Littler, J.A.H., Hatton, M., Johnson, P.W.M., Martin, W.M.C., Rankin, E.M., James, L.E., Gregory, W.M., Qian, W. and Lee, S.M. (2005) Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group. Journal of Clinical Oncology, 23, (1), 142-153. (doi:10.1200/JCO.2005.03.037).
Harper-Wynne, C.L., Sumpter, K., Ryan, C., Priest, K., Norton, A., Ross, P., Ford, H.E.R., Johnson, P. and O'Brien, M.E.R. (2005) Addition of SRL 172 to standard chemotherapy in small cell lung cancer (SCLC) improves symptom control. Lung Cancer, 47, (2), 289-290. (doi:10.1016/j.lungcan.2004.08.013).
Michels, J., O'Neill, Jason W., Dallman, Claire L., Mouzakiti, Amalia, Habens, Fay, Brimmell, Matthew, Zhang, Kam Y.G., Craig, Ruth W., Marcusson, Eric G., Johnson, Peter W.M. and Packham, Graham (2004) Mcl-1 is required for Akata6 B-lymphoma cell survival and is converted to a cell death molecule by efficient caspase-mediated cleavage. Oncogene, 23, (28), 4818-4827. (doi:10.1038/sj.onc.1207648).
Stevenson, Freda K., Ottensmeier, Christian H., Johnson, Peter, Zhu, Delin, Buchan, Sarah L., McCann, Katy J., Roddick, Joanne S., King, Andrew T., McNicholl, Feargl, Savelyeva, Natalia and Rice, Jason (2004) DNA vaccines to attack cancer. Proceedings of the National Academy of Sciences of the United States of America, 101, (s2), 14646-14652. (doi:10.1073/pnas.0404896101).
Rao, S., Watkins, D., Cunningham, D., Dunlop, D., Johnson, P., Selby, P., Hancock, B.W., Fegan, C., Culligan, D., Schey, S., Morris, T.C.M., Lissitchkov, T., Oliver, J.W. and Holmlund, J.T. (2004) Phase II study of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C alpha, in patients with previously treated low-grade non-Hodgkin's lymphoma. Annals of Oncology, 15, (9), 1413-1418. (doi:10.1093/annonc/mdh359).
Du, Yong, Honeychurch, Jamie, Cragg, Mark S., Bayne, Mike, Glennie, Martin J., Johnson, Peter W.M. and Illidge, Tim M. (2004) Antibody-induced intracellular signaling works in combination with radiation to eradicate lymphoma in radioimmunotherapy. Blood, 103, (4), 1485-1494. (doi:10.1182/blood-2003-06-2037).
Packham, Graham, Cutress, Ramsay I., Townsend, Paul A., Sharp, Adam and Johnson, Peter W.M. (2003) BAG-1 potentiates oestrogen dependent transcription and protects breast cancer cells from stress-induced growth inhibition. British Journal of Cancer, 88, (Supplement 1), p.S59. (doi:10.1038/sj.bjc.6600375).
Banks, Charmian, Bateman, Adrian, Payne, Richard, Johnson, Penny and Sheron, Nick (2003) Chemokine expression in IBD. Mucosal chemokine expression is unselectively increased in both ulcerative colitis and Crohn's disease. Journal of Pathology, 199, (1), 28-35. (doi:10.1002/path.1245).
Cragg, Mark S., Morgan, Suzanne M., Chan, H.T. Claude, Morgan, B. Paul, Filatov, A.V., Johnson, Peter W.M., French, Ruth R. and Glennie, Martin J. (2003) Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood, 101, (3), 1045-1052. (doi:10.1182/blood-2002-06-1761).
Mirnezami, Alexander H., Campbell, Sandra J., Darley, Matthew, Primrose, John N., Johnson, Peter W.M. and Blaydes, Jeremy P. (2003) Hdm2 recruits a hypoxia-sensitive corepressor to negatively regulate p53-dependent transcription. Current Biology, 13, (14), 1234-1239. (doi:10.1016/S0960-9822(03)00454-8).
Cutress, Ramsey I., Townsend, Paul A., Sharp, Adam, Maison, Anna, Wood, Lynn, Lee, Ron, Brimmell, Matthew, Mullee, Mark A., Johnson, Peter W.M., Royle, Gavin T., Bateman, Adrian C. and Packham, Graham (2003) The nuclear BAG-1 isoform, BAG-1L, enhances oestrogen-dependent transcription. Oncogene, 22, (32), 4973-4982. (doi:10.1038/sj.onc.1206688). (PMID:12902980).
Cutress, Ramsay I., Townsend, Paul A., Wood, Lynn, Brimmell, Matthew, Maison, Anna, Lee, Ron, Mullee, Mark A., Johnson, Peter W.M., Royle, Gavin T., Bateman, Adrian C. and Packham, Graham (2002) Nuclear BAG-1 expression predicts survival from breast cancer, and potentiates oestrogen dependent transcription. British Journal of Cancer, 86, (Supplement 1), p.S32. (doi:10.1038/sj.bjc.6600406).
Zhu, Delin, McCarthy, Helen, Ottensmeier, Christian H., Johnson, Peter, Hamblin, Terry J. and Stevenson, Freda K. (2002) Acquisition of potential N-glycosylation sites in the immunoglobulin variable region by somatic mutation is a distinctive feature of follicular lymphoma. Blood, 99, (7), 2562-2568. (doi:10.1182/blood.V99.7.2562).
Mann, Jelena, Oakley, Fiona, Johnson, Peter W.M. and Mann, Derek A. (2002) CD40 induces interleukin-6 gene transcription in dendritic cells: regulation by TRAF2, AP-1, NF-κB, AND CBF1. The Journal of Biological Chemistry, 277, (19), 17125-17138. (doi:10.1074/jbc.M109250200).
Cutress, R.I., Townsend, P.A., Bateman, A.C., Johnson, P.W., Ryder, K., Barnes, D.M. and Packham, G. (2001) BAG-1 immunostaining and survival in early breast cancer. Journal of Clinical Oncology, 19, (16), 3706-3707. (PMID:11504752).
Harvey, M.L., Illidge, T. and Johnson, P. (2001) Antibodies in the treatment of lymphoma. Clinical Oncology, 13, (4), 251-261. (doi:10.1053/clon.2001.9264).
Protheroe, A.S., Pickard, C., Johnson, Peter W.M., Craddock, T., Shefta, J., Short, K., Lancaster, F., Selby, P. J., Henwood, J. and Boylston, A.W. (2000) Persistence of clonal T-cell expansions following high-dose chemotherapy and autologous peripheral blood progenitor cell rescue. British Jurnal of Haematology, 111, (3), 766-773.
MacCarthy-Morrogh, Lucy, Wood, Lynn, Brimmell, Matthew, Johnson, Peter W. and Packham, Graham (2000) Identification of a novel human BCL-X promoter and exon. Oncogene, 19, (48), 5534-5538.
Davies, F. E., Rawstron, A. C., Pratt, G., Coupe, R., Clarke, D., Lubenko, A., Short, K., Perren, T. J., Selby, P. J., Maclennan, S., Major, K., Woodhead, V., Robinson, F., Child, J. A., Smith, G. M., Johnson, Peter W.M. and Morgan, G. J. (2000) Positive and negative selection to reduce tumour contamination in peripheral blood stem cell harvests. Hematological Oncology, 18, (3), 111-120. (doi:10.1002/1099-1069(200009)18:3<111::AID-HON657>3.0.CO;2-#).
Crawley, C.R., Foran, J.M., Gupta, R. K., Rohatiner, A.Z., Summers, K., Matthews, J., Micallef, I.N., Radford, J.A., Johnson, S.A., Johnson, Peter W.M., Sweetenham, J.W. and Lister, T. A. (2000) A phase II study to evaluate the combination of fludarabine, mitoxantrone and dexamethasone (FMD) in patients with follicular lymphoma. Annals of Oncology , 11, (7), 861-865.
Simnett, S.J., Stewart, L. A., Sweetenham, J., Morgan, G. and Johnson, Peter W.M. (2000) Autologous stem cell transplantation for malignancy: a systematic review of the literature. Clinical and Laboratory Haematology, 22, (2), 61-72.
Child, J. A., Johnson, S. A., Rule, S., Smith, G. M., Morgan, G. J., Johnson, Peter W.M., Prentice, A. G., Tollerfield, S. M. and Wareham, E. (2000) FLUDAP: salvage chemotherapy for relapsed/refractory aggressive non-Hodgkin's lymphoma. Leukemia & Lymphoma, 37, (3-4), 309-317. (doi:10.3109/10428190009089431).
Foran, J.M., Gupta, R. K., Cunningham, D., Popescu, R. A., Goldstone, A. H., Sweetenham, J.W., Pettengell, R., Johnson, Peter W.M., Bessell, E., Hancock, B., Summers, K., Hughes, J. , Rohatiner, A. Z. and Lister, T. A. (2000) A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response. British Journal of Haematology, 109, (1), 81-88.
Foran, J. M., Rohatiner, A.Z., Cunningham, D., Popescu, R. A., Solal-Celigny, P., Ghielmini, M., Coiffier, B., Johnson, Peter W.M., Gisselbrecht, C., Reyes, F., Radford, J. A., Bessell, E. M., Souleau, B., Benzohra, A. and Lister, T. A. (2000) European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. Journal of Clinical Oncology, 18, (2), 317-324.
Foran, J.M., Cunningham, D., Coiffier, B., Solal-Celigny, P., Reyes, F., Ghielmini, M., Johnson, Peter W.M., Gisselbrecht, C., Bradburn, M., Matthews, J. and Lister, T. A. (2000) Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response. Annals of Oncology , 11, (Supplement 1), S117-S121. (doi:10.1093/annonc/11.suppl_1.S117).


Research Interests

Peter Johnson specialises in the treatment of lymphoma, and is the Chief Investigator for several lymphoma trials nationally and internationally.

He works closely with the immunologists of the academic group, in particular for basic and translational research into the use of immunostimulatory antibodies. He is the Chief investigator in a phase I clinical trial of an agonistic chimerised anti-CD40 antibody which was developed with Martin Glennie's group, and which is being used to test the idea that CD40 ligation may be able to enhance antigen presentation via licencing of professional APCs, while at the same time directing killing of CD40+ tumour cells.

His current international trials include the RATHL study in advanced Hodgkin lymphoma, investigating the use of FDG-PET scanning to guide treatment intensification or de-escalation, to optimize the balance between efficacy and toxicity. He also leads the REMoDL-B study, the first to use gene expression profiling in real time to stratify treatment for diffuse large B-cell lymphoma.

Academic unit:  Cancer Sciences Academic Unit

Affiliate academic units:  Cancer Sciences Research group


National Responsibilities

Chief Clinician, Cancer Research UK
National Cancer Research Institute, Board member
UK Clinical Research Collaboration, Board member
Academy of Medical Sciences Review of Research Governance and Regulation
National Cancer Research Institute, Lymphoma Clinical Studies Group (Chair from 2005-2011)
National Cancer Research Institute, Clinical and Translational Steering Group, Chair
Genome England, Scientific Advisory Board

International Responsibilities

International Conference on Malignant Lymphoma, Organising Committee
International Symposium on Hodgkin Lymphoma, Scientific Committee
Schweiz. Arbeitsgemeinschaft für Klinische Krebsforschung (SAKK), International advisor
Cancer Immunotherapy (CIMT) Consortium, Executive Board

Postgraduate Student Supervision

22 successfully completed since 1999
2 in progress

Teaching Responsibilities

Personal tutor

Clinical attachments for final year BM5 students

PhD Training account for Clinical Research Fellows


Professor Peter Johnson
Tel: (023) 8120 6186 Fax: (023) 8120 5152 Email:

Room Number: SGH/CSB/MP824